Scandinavian journal of gastroenterology
-
Scand. J. Gastroenterol. · Apr 2014
Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring.
Most previous studies have failed to demonstrate any effect of maternal use of 5-aminosalicylates (5-ASA) on malformation risk, but the number of infants studied have, in most cases, been low. The objective of the study was to get data from a large study with prospectively ascertained exposure information. ⋯ Infants born of women who use 5-ASA drugs in early pregnancy have an increased risk of a congenital malformation, notably a cardiovascular defect. This could be a drug effect or an effect of an active inflammatory bowel disease.